Yazar "Molinas Mandel, Nil" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study
    (2024) Ölmez, Ömer Fatih; Bilici, Ahmet; Er, Özlem; Bişgin, Atıl; Sevinç, Alper; Akman, Tülay; Uslu, Rüçhan; Molinas Mandel, Nil; Yalçın, Şuayib; Teomete, Mehmet; Görümlü, Gürbüz; Demir, Atakan; Namal, Esat; Alıcı, Süleyman; Selçukbiricik, Fatih; Bavbek, Sevil; Paksoy, Fatma; Başaran, Gül; Özer, Leyla; Şener, Nur; Harputluoğlu, Hakan; Kaya, Ali Osman; Yazar, Aziz; Afşar, Çiğdem Usul; Göker, Erdem; Şen, Fatma; Gököz Doğu, Gamze; Şeker, Mesut; Özkan, Metin; Türken, Orhan; Özveren, Ahmet; Orhan, Bülent; Yumuk, Fulden; Üskent, Necdet; Saip, Pınar; Şanlı, Ulus Ali; Dişel, Umut; Berk, Veli; Alakavuklar, Mehmet
    Objective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced solid malignancies. We then evaluated the impact of these informed choices on patient treatment outcomes. Methods: The study encompassed 234 adult patients (mean age: 52.7 ± 14.3 years, 54.7% women) who were diagnosed with solid tumours at 21 different medical centres in Turkey. Remarkably, 67.9% of the patients exhibited metastasis at the time of diagnosis. We utilized an OncoDNA (Gosselies, Belgium) platform (OncoDEEP) integrating next-generation sequencing with additional tests to harvest complex molecular profiling data. The results were analyzed in relation with two specific outcomes: (i) the impact on therapeutic decisions, including formulation or modifications, and (ii) associated treatment response. Results: Out of the 228 patients with final molecular profiling results, 118 (50.4%) had their treatment modified, whilst the remaining 110 (47.0%) did not. The response rates were comparable, with 3.9 versus 3.4% for complete response, 13.6 versus 29.3% for partial response, 66.9 versus 51.7% for progressive disease and 15.5 versus 15.5% for stable disease for treatments informed and not informed by complex molecular profiling, respectively (P = 0.16). Conclusion: Our real-world findings highlight the significant impact of complex molecular profiling on the treatment decisions made by oncologists for a substantial portion of patients with advanced solid tumours. Regrettably, no significant advantage was detected in terms of treatment response or disease control rates.
  • Küçük Resim Yok
    Öğe
    Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study
    (American Society of Clinical Oncology, 2020) Disel, Umut; Köse, Fatih; Bilici, Ahmet; Özgüroğlu, Mustafa; Sağlam, Sezer; Şeker, Mesut; Aksoy, Sercan; Tek, İbrahim; Eralp, Yeşim; Molinas Mandel, Nil; Demir, Gökhan; Arslan, Çağatay; Demiray, Mutlu; Salepçi, Taflan; Öztürk, Mehmet Akif; Selçukbiricik, Fatih; Temizaş, Gökçe; Fidan, Ebru Gül
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Prognostic significance of tumor tissue NeuGcGM3 ganglioside expression in patients receiving racotumomab immunotherapy
    (Hindawi Ltd., 2020) Üskent, Necdet; Ayla, Şule; Molinas Mandel, Nil; Özkan, Metin; Teomete, Mehmet; Baloğlu, Hüseyin; Aydinçer, Cenk; Yergök, Hale; Doğan, Ender; Berk, Barkın; Yazar, Aziz
    Expression ofN-glycolyl GM3 (NeuGcGM3) ganglioside was detected in the tumor specimens of patients who were on Racotumomab anti-idiotype vaccine maintenance treatment, and prognostic significance as a biomarker was investigated. No statistically significant association was observed in the multivariate analysis between overall survival and tissue NeuGcGM3 IHC levels. Although numerically there was a difference favoring less intense IHC for better prognosis, this did not reach statistical power. However, there was a strong correlation between Racotumomab doses and overall survival (OS). Mean OS of the patient with more than 10 Racotumomab application was significantly longer than the patient who had less than 10 injections (70.7 months vs. 31.1 months, p<0.001). We propose that, regardless of staining intensity, the presence of NeuGcGM3 in patient tissues might be an indicator of benefit in Racotumomab treatment.